Aim and background: A stability-indicating gradient reverse phase liquid chromatographic (RP-LC) method was developed for the quantitative determination of related substances of guaifenesin in pharmaceutical formulations. Materials and methods: The baseline separation for guaifenesin and all impurities was achieved by a gradient elution method. The mobile phase A contains a mixture of 0.02 M KH 2 PO 4 (pH 3.2) and methanol in the ratio of 90:10 v/v, while the mobile phase B contains 0.02 M KH 2 PO 4 of the mobile phase was 0.8 ml/min with a column temperature of 25°C and detection wavelength at 273 nm. Results: Guaifenesin was subjected to the stress conditions of oxidative, acid, base, hydrolytic, thermal, and photolytic degradation. Conclusion:
INTRODUCTION
Guaifenesin, (+)-3-(2-methoxyphenoxy)-propane-1,2-diol, is a widely used expectorant, useful for the symptomatic relife of respiratory conditions [ Figure 1 ]. Its empirical formula is C 10 H 14 O 4 , which corresponds to a molecular weight of aromatic taste. Its solid oral dosage form is available as extended release tables for oral administration. [1] In the literature survey, there were several LC assay methods have been reported for determination of guaifenesin in pharmaceutical preparation [2] [3] [4] [5] [6] [7] [8] [9] and in human plasma by LC-MS. [10] [11] [12] So far to our present knowledge, no stability indicating the HPLC method has been reported for the estimation of guaifenesin impurities and degradation products present in pharmaceutical formulation. Hence, we have developed a simple reproducible gradient stability indicating the reverse phase liquid chromatographic (RP-LC) method for the quantitative determination of in guaifenesin pharmaceutical dosage forms. The developed LC method was precision, accuracy, and robustness. Force degradation studies were performed on the placebo and drug products to show the stability-indicating nature of the method. These studies were performed in accordance with established ICH guidelines. [13] [14] [15] Access this article online 
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MATERIALS AND METHODS
Chemicals and reagents
The samples of guaifenesin-extended release tablets and its impurities were supplied by Dr. Reddy's laboratories limited, Hyderabad, India. The HPLC grade methanol and analytical grade KH 2 PO 4 and ortho-phosphoric acid were purchased from Merck, Mumbai, India. High purity water was prepared by (Millipore, Milford, MA, USA).
Equipments
The chromatography analysis was performed using Waters Alliance 2695 separation module (Waters Corporation, Milford, USA) equipped with 2489 UV/ and forced degradation studies), degasser, quaternary pump, and auto sampler system. The output signals were monitored and processed using Empower 2 software. Cintex digital water bath was used for hydrolysis studies. Photo-stability studies were carried out in the photo-stability chamber (Sanyo, Leicestershire, UK). Thermal stability studies were performed in a dry air oven (Cintex, Mumbai, India). The pH of the solutions was measured by a pH meter
Chromatographic conditions
The method was developed using a Waters Symmetry 
Preparation of sample solution
Tablet powder equivalent to 600 mg of guaifenesin was dissolved in diluent with sonication for 10 min to give a solution containing 2.4 mg/mL drug. This solution was centrifuged at 4000 rpm for 10 min.
RESULTS AND DISCUSSION
Method development and optimization
The aim of the study was to separate all known and unknown degradation products from guaifenesin and their simultaneous determination in pharmaceutical in the mobile phase using C-18 and C-8 stationary phase columns. To ensure great resolution between all known and unknown degradation compounds, the C-18 stationary phase with an end-capping was used. In this case, the optimized mobile phase was constituted by solvent A (90:10 v/v mixture of 0.02 M KH 2 PO 4 , pH adjusted to 3.2 with orthophosphoric acid and methanol) and B (10:90 v/v mixture of 0.02 M KH 2 PO 4 program (time (min)/%B) was set 0/0, 50/40, 52/0, and min. The column temperature was maintained at 25°C, and the eluted compounds were monitored at the wavelength of 273 nm.
Validation of the method
The proposed method was validated as per ICH guidelines. [13] [14] [15] The following validation characteristics studies were performed at 2.4 mg/mL concentration of guaifenesin on tablet to provide an indication of proposed method. The stress conditions employed for degradation study included acid hydrolysis (1 N HCl at 60°C for 12 h), base hydrolysis (1 N NaOH at 60°C for 12 h), oxidation (1% H 2 O 2 at room temperature for 12 h), hydrolytic (water at 60°C for 12 h), thermal (105°C for 24 h), and photolytic degradation (drug product exposed to visible light for 240 h resulting an overall illustration 1.2 million lux hours and UV light 2 at 25°C). Sight degradation was observed under acid and base stress conditions [ Figures 2 and 3] . Guaifenesin found stable under oxidative, hydrolytic, thermal, and photolytic stress conditions. The peak purity test was carried out for the guaifenesin peak by using the PDA detector in stress samples. The mass balance (% assay + % sum of all degradants + % sum of all impurities) results were calculated and found to be more than 95% [ Table 1 ]. The purity of guaifenesin indicating power of the developed method.
robustness.
System suitability
System suitability shall be checked for the conformance of suitability and reproducibility of chromatographic system for analysis. System suitability was determined before sample analysis from duplicate injections guaifenesin. The acceptance criteria were USP tailing factor not more than 2.0 and the area similarity ratio between 0.9 and 1.1 for the guaifenesin peak from duplicate injections of standard preparation. All critical parameters tested met the acceptance criteria.
the analyte response in the presence of its potential impurities and degradation products. Placebo interference was evaluated by analyzing the placebo prepared as per the test method. No peak due to placebo detected at the retention time of guaifenesin method for guaifenesin was carried out in the presence of its impurities and degradation products. Stress Table 2 .
determined at a signal-to-noise ratio of 3:1 and 10:1, respectively, by injecting a series of dilute solutions with known concentrations. The precision study was also carried out at the LOQ level by injecting six impurities and calculating the % RSD of the area [ Table 2 ].
Linearity
Linearity test solutions were prepared by diluting the stock solutions to the required concentrations. The solutions were prepared at six concentration levels of peak vs. analyte concentrations. The correlation at 100% response was within 5% [ Table 3 . 
Robustness
To determine the robustness of the developed method, experimental conditions were deliberately altered and guaiacol with respect to guaifenesin; and system suitability parameters for guaifenesin standard was recorded. The variables evaluated in the study temperature (± ± 0.2 mL/min), and % organic in the mobile phase (±10%). In all the deliberate varied chromatographic conditions, all analytes were adequately resolved and the elution order remained unchanged. The area ratio for the guaifenesin peak from standard solution was between 0.9 and 1.1 and the tailing factor was less than 1.1 [ Table 4 ].
Stability of solution and the mobile phase
The solution stability of guaifenesin and its impurities were determined by leaving test solution and standard temperature for 48 h and measured the amount of both impurities at every 24 h against freshly prepared standard solution. The stability of the mobile phase was also determined by freshly prepared solutions of guaifenesin and its impurities at 24 h interval for 48 h. The mobile phase was not changed during the study.
guaiacol was within ± 10% during solution stability and mobile phase stability. The results from solution stability and mobile phase stability experiments and mobile phase were stable up to 48 h.
CONCLUSIONS
was developed and validated for quantitative analysis of guaifenesin in pharmaceutical dosage forms. The method found to be precise, accurate, linear, robust, and rugged during validation. Satisfactory results were obtained from the validation of the method. The method is stability indicating and can be used for routine analysis of production samples and to check the stability of the guaifenesin tablets. 
